Literature DB >> 15602662

The clinical trial imperative.

Debbie Gipson, Howard Trachtman.   

Abstract

As clinical judgment has joined forces with evidence-based medicine, nephrologists critically assess the validity of the data available to support therapeutic decisions for children with kidney disease. Unfortunately, a paucity of data often prevents the practice of evidence-based medicine. Three scenarios illustrating the status of evidence and clinical decision making are provided. A review of the pediatric nephrology literature supports a call for general support of ongoing clinical trials and encourages the creation of additional feasible clinical trials to improve the practice of medicine.

Entities:  

Mesh：

Year:  2004        PMID： 15602662     DOI： 10.1007/s00467-004-1681-z

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


  27 in total

1.  Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis.

Authors:  J M Kaplan; S H Kim; K N North; H Rennke; L A Correia; H Q Tong; B J Mathis; J C Rodríguez-Pérez; P G Allen; A H Beggs; M R Pollak
Journal:  Nat Genet       Date:  2000-03       Impact factor: 38.330

Review 2.  New CRRT systems: impact on dose delivery.

Authors:  C Ronco; R Bellomo
Journal:  Am J Kidney Dis       Date:  1997-11       Impact factor: 8.860

3.  Successful mycophenolate mofetil treatment of glomerular disease.

Authors:  W A Briggs; M J Choi; P J Scheel
Journal:  Am J Kidney Dis       Date:  1998-02       Impact factor: 8.860

4.  Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children.

Authors:  P Tarshish; J N Tobin; J Bernstein; C M Edelmann
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

5.  A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children.

Authors:  K V Lieberman; A Tejani
Journal:  J Am Soc Nephrol       Date:  1996-01       Impact factor: 10.121

6.  Relationship of dose of hemodialysis and cause-specific mortality.

Authors:  W E Bloembergen; D C Stannard; F K Port; R A Wolfe; J A Pugh; C A Jones; J W Greer; T A Golper; P J Held
Journal:  Kidney Int       Date:  1996-08       Impact factor: 10.612

7.  Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome.

Authors:  Rainer G Ruf; Anne Lichtenberger; Stephanie M Karle; Johannes P Haas; Franzisco E Anacleto; Michael Schultheiss; Isabella Zalewski; Anita Imm; Eva-Maria Ruf; Bettina Mucha; Arvind Bagga; Thomas Neuhaus; Arno Fuchshuber; Aysin Bakkaloglu; Friedhelm Hildebrandt
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

8.  Effects of dose of dialysis on morbidity and mortality.

Authors:  R M Hakim; J Breyer; N Ismail; G Schulman
Journal:  Am J Kidney Dis       Date:  1994-05       Impact factor: 8.860

9.  The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children.

Authors: 
Journal:  J Pediatr       Date:  1981-04       Impact factor: 4.406

10.  Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study.

Authors:  E G Lowrie; N M Laird; T F Parker; J A Sargent
Journal:  N Engl J Med       Date:  1981-11-12       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.